Loveday Marian, Gandhi Neel R, Khan Palwasha Y, Theron Grant, Hlangu Sindisiwe, Holloway Kerry, Chotoo Sunitha, Singh Nalini, Marais Ben J
HIV and Other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Durban, South Africa.
CAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
EClinicalMedicine. 2024 Sep 5;76:102821. doi: 10.1016/j.eclinm.2024.102821. eCollection 2024 Oct.
There have been no detailed descriptions of infants born to mothers treated for drug resistant TB in pregnancy. Critical case history assessment is important to identify risks and guide clinical practice.
In a cohort of pregnant women with multidrug or rifampicin resistant (MDR/RR)-TB enrolled between 1 January 2013 and 31 December 2022, we followed mother-infant pairs until the infant was 12 months old. We performed critical case history assessments to explore potential mechanisms of transmission to the infant, and to describe the clinical presentation and disease trajectories observed in infants diagnosed with TB.
Among 101 mother-infant pairs, 23 (23%) included infants diagnosed with TB disease; 16 were clinically diagnosed and seven had microbiological confirmation (five MDR/RR-TB, two drug-susceptible TB). A positive maternal sputum culture at the time of delivery was significantly associated with infant TB risk (p = 0.023). Of the 12 infants diagnosed with TB in the first three months of life, seven (58%) of the mothers were culture positive at delivery; of whom four reported poor TB treatment adherence. However, health system failures, including failing to diagnose and treat maternal MDR/RR-TB, inadequate screening of newborns at birth, not providing appropriate TB preventive therapy (TPT), and transmission from non-maternal sources also contributed to TB development in infants.
Infants born to mothers with MDR/RR-TB are at greatest risk if maternal adherence to MDR/RR-TB treatment or antiretroviral therapy (ART) is sub-optimal. In a high TB incidence setting, infants are also at risk of non-maternal household and community transmission. Ensuring maternal TB diagnosis and appropriate treatment, together with adequate TB screening and prevention in all babies born to mothers or households with TB will minimise the risk of infant TB disease development.
South African Medical Research Council.
目前尚无关于孕期接受耐多药结核病治疗的母亲所生婴儿的详细描述。关键病史评估对于识别风险和指导临床实践很重要。
在2013年1月1日至2022年12月31日期间纳入的一组耐多药或耐利福平(MDR/RR)结核病孕妇中,我们对母婴对进行随访,直至婴儿12个月大。我们进行了关键病史评估,以探索传播给婴儿的潜在机制,并描述诊断为结核病的婴儿的临床表现和疾病轨迹。
在101对母婴对中,23对(23%)包括诊断为结核病的婴儿;16例为临床诊断,7例有微生物学确诊(5例MDR/RR-TB,2例药物敏感结核病)。分娩时母亲痰培养阳性与婴儿患结核病风险显著相关(p = 0.023)。在生命前三个月诊断为结核病的12例婴儿中,7例(58%)母亲分娩时痰培养阳性;其中4例报告结核病治疗依从性差。然而,卫生系统的失误,包括未能诊断和治疗母亲的MDR/RR-TB、出生时对新生儿筛查不足、未提供适当的结核病预防性治疗(TPT)以及非母亲来源的传播,也导致了婴儿结核病的发生。
如果母亲对MDR/RR-TB治疗或抗逆转录病毒疗法(ART)的依从性欠佳,那么患有MDR/RR-TB的母亲所生婴儿面临的风险最大。在结核病高发地区,婴儿也有来自非母亲家庭和社区传播的风险。确保母亲结核病的诊断和适当治疗,以及对所有结核病母亲或家庭所生婴儿进行充分的结核病筛查和预防,将使婴儿患结核病的风险降至最低。
南非医学研究理事会。